Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

Next Previous
Trial Profile

A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PR 001 (Primary) ; Methylprednisolone; Prednisone; Rituximab; Sirolimus
  • Indications Parkinson's disease
  • Focus Adverse reactions; Biomarker; First in man
  • Acronyms PROPEL
  • Sponsors Prevail Therapeutics

Most Recent Events

  • 10 Apr 2025 Planned End Date changed from 1 Jun 2029 to 31 Dec 2030.
  • 10 Apr 2025 Planned primary completion date changed from 1 Jun 2029 to 31 Dec 2030.
  • 02 May 2023 Planned End Date changed from 1 Apr 2028 to 1 Jun 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top